Neovasc Inc. ( NVCN) Stock. Should you Buy or Sell? $ 7.42
0.03 (0.40 %)
Neovasc Inc. Analysis
Updated on 10-09-2022| Symbol | NVCN |
| Price | $7.42 |
| Beta | 2.500 |
| Volume Avg. | $14.43 thousand |
| Market Cap | $20.35 M |
| 52 Week Range | $4.59 - $21.5 |
Neovasc Inc. opened the day at $7.42 which is +'0.40 % on yesterday's close. Neovasc Inc. has a 52 week high of $21.5 and 52 week low of $4.59, which is a difference of $16.91. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $20.35 M and total net profit is $2547406 which means the company is trading at 7.99 times profit to market capitalization. Theoretically, if you were to buy Neovasc Inc. for $20.35 M, it would take 15 years to get your money back. Neovasc Inc. are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Neovasc Inc. Stock Forecast - Is Neovasc Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.612 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -12.150 |
Valuing Neovasc Inc.
| Price Book Value Ratio | 0.460 | Price To Book Ratio | 0.460 |
| Price To Sales Ratio | 7.432 | Price Earnings Ratio | -0.612 |
How liquid is Neovasc Inc.
| Current Ratio | 12.879 |
| Quick Ratio | 12.241 |
Debt
| Debt Ratio | 0.271 | Debt Equity Ratio | 0.372 |
| Long Term Debt To Capitalization | 0.218 | Total Debt To Capitalization | 0.222 |
Latest news about Neovasc Inc.
VANCOUVER and MINNEAPOLIS, Aug. 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New York City. Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 1:30 pm ET on Tuesday, September 13, 2022.
Neovasc Inc. (NASDAQ:NVCN ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President and Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participants Vernon Bernardino - H. C. Wainwright Operator Greetings and welcome to Neovasc Inc Second Quarter 2022 Earnings Call.
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June 15-16, 2022. Neovasc's Chief Operating Officer, Bill Little, will be presenting at 1:45 pm ET on Wednesday, June 15.The presentation can be accessed here. Additionally, a recording of the...
VANCOUVER and MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen, Neovasc's President and Chief Executive Officer, will be presenting at 11:00 am ET on Wednesday, May 25.
Neovasc Inc. (NASDAQ:NVCN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President and Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participants Vernon Bernardino - H.C. Wainwright Operator Greetings and welcome to Neovasc First Quarter 2022 Earnings Conference Call.
About Neovasc Inc.
Description :
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
